Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACASA-TAVI
2021-001554-61Phase 3Active
- Sponsor
- Oslo University Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin, apixaban, rivaroxaban and edoxaban in aortic stenosis (AS) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Co-primary efficacy endpoint, Co-primary safety endpoint and 1 more. Started Jun 2021; status: active.
02
Drugs
aspirinapixabanrivaroxabanedoxaban
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on 2021-001554-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001554-61.